MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 314208 | Name: Aclidinium Bromide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Aclidinium bromide is a long-acting anticholinergic bronchodilator approved by the FDA in 2012 for use in the management of chronic obstructive pulmonary disease (COPD) which includes chronic bronchitis and emphysema. It is not however used for acute exacerbations. Aclidinium bromide is an inhalation powder promoted by Forest Pharmaceuticals in the US under the trade name Tudorza Pressair. It is also manufactured and marketed by Menarini Pharmaceuticals in the EU under the trade name Bretaris Genuair, in the UK as Eklira Genuair and in the Canada as Tudorza Genuair.

Chemical Structure

Aclidinium Bromide
Aclidinium Bromide
CAS#320345-99-1 (bromide)

Theoretical Analysis

MedKoo Cat#: 314208

Name: Aclidinium Bromide

CAS#: 320345-99-1 (bromide)

Chemical Formula: C26H30BrNO4S2

Exact Mass: 563.0800

Molecular Weight: 564.55

Elemental Analysis: C, 55.31; H, 5.36; Br, 14.15; N, 2.48; O, 11.34; S, 11.36

Price and Availability

Size Price Availability Quantity
10mg USD 250.00 2 Weeks
25mg USD 450.00 2 Weeks
50mg USD 750.00 2 Weeks
100mg USD 1,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
320345-99-1 (bromide) 727649-81-2 (cation)
Synonym
LAS 34273; LAS-34273; LAS34273; LAS-W 330; Eklira; Genuair; Tudorza; Genuair; Bretaris; Genuair;
IUPAC/Chemical Name
[(8R)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-8-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate bromide
InChi Key
XLAKJQPTOJHYDR-QTQXQZBYSA-M
InChi Code
InChI=1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1
SMILES Code
O=C(O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)C(C4=CC=CS4)(O)C5=CC=CS5.[Br-]
Appearance
solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO.
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 564.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: D'Urzo AD, Singh D, Donohue JF, Chapman KR, Wise RA. Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update. Expert Rev Respir Med. 2021 Sep;15(9):1093-1106. doi: 10.1080/17476348.2021.1920403. Epub 2021 Jun 17. PMID: 34137664. 2: Stone LE, Skelley JW, Kyle JA, Elmore LK. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Am J Health Syst Pharm. 2014 Mar 1;71(5):386-93. doi: 10.2146/ajhp130077. PMID: 24534593. 3: Cazzola M, Page CP, Matera MG. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013 Jun;14(9):1205-14. doi: 10.1517/14656566.2013.789021. Epub 2013 Apr 9. PMID: 23566013. 4: Woods JA, Nealy KL, Barrons RW. Aclidinium bromide: an alternative long- acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease. Ann Pharmacother. 2013 Jul-Aug;47(7-8):1017-28. doi: 10.1345/aph.1S002. Epub 2013 Jun 4. PMID: 23737515. 5: Haley R, Gupta N, Sethi S. Aclidinium bromide and formoterol fumarate for the maintenance treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol. 2020 Feb;13(2):103-113. doi: 10.1080/17512433.2020.1717334. Epub 2020 Jan 29. PMID: 31951778. 6: Gupta V, Singh D. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2012 Dec;6(6):581-8. doi: 10.1586/ers.12.61. PMID: 23234445. 7: Joos GF. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Drugs Today (Barc). 2012 Dec;48(12):757-63. doi: 10.1358/dot.2012.48.12.1885871. PMID: 23243632. 8: Lal C, Strange C. Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2015 Feb;16(3):427-34. doi: 10.1517/14656566.2015.1000861. Erratum in: Expert Opin Pharmacother. 2015 Apr;16(6):939. PMID: 25597386. 9: Malerba M, Radaeli A, Santini G, Morjaria J, Mores N, Mondino C, Macis G, Montuschi P. The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Discov. 2018 Jun;13(6):563-577. doi: 10.1080/17460441.2018.1455661. Epub 2018 Apr 4. PMID: 29616842. 10: Ni H, Soe Z, Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014 Sep 19;2014(9):CD010509. doi: 10.1002/14651858.CD010509.pub2. PMID: 25234126; PMCID: PMC8922974. 11: Cazzola M. Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. Curr Opin Investig Drugs. 2009 May;10(5):482-90. PMID: 19431081. 12: Sentellas S, Ramos I, Albertí J, Salvà M, Antón F, Miralpeix M, Beleta J, Gavaldà A. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci. 2010 Mar 18;39(5):283-90. doi: 10.1016/j.ejps.2010.01.004. Epub 2010 Jan 20. PMID: 20093184. 13: Jones P. Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review. Adv Ther. 2013 Apr;30(4):354-68. doi: 10.1007/s12325-013-0019-2. Epub 2013 Apr 2. PMID: 23553509. 14: Institute for Quality and Efficiency in Health Care. Aclidinium Bromide -- Benefit Assessment According to §35a Social Code Book V [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2012 Dec 21. Extract of Dossier Assessment No. A12-13. PMID: 27905744. 15: Aclidinium Bromide (Tudorza Genuair): Long-term Maintenance Bronchodilator Treatment in Patients with Chronic Obstructive Pulmonary Disease [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug. PMID: 26962618. 16: Moitra S, Bhome AB, Brashier BB. Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date. Drug Des Devel Ther. 2015 Apr 7;9:1989-99. doi: 10.2147/DDDT.S53150. PMID: 25897208; PMCID: PMC4396584. 17: D'Urzo AD, Singh D, Donohue JF, Chapman KR. Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619850725. doi: 10.1177/1753466619850725. PMID: 31096854; PMCID: PMC6535700. 18: Matera MG, Sanduzzi A, Alfano R, Cazzola M. Aclidinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema. Expert Rev Clin Pharmacol. 2016 Jun;9(6):771-7. doi: 10.1586/17512433.2016.1169173. Epub 2016 Apr 7. PMID: 26998725. 19: Sims MW, Panettieri RA Jr. Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;6:457-66. doi: 10.2147/COPD.S15524. Epub 2011 Sep 16. PMID: 22003291; PMCID: PMC3186744. 20: Jones PW. Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015 Mar 26;10:677-87. doi: 10.2147/COPD.S76520. PMID: 25848244; PMCID: PMC4381904.